Development of a scoring system to predict risk of death in exacerbations of chronic obstructive pulmonary disease (COPD) requiring assisted ventilation.

ISRCTN ISRCTN16977236
DOI https://doi.org/10.1186/ISRCTN16977236
Secondary identifying numbers Protocol ref v4.1
Submission date
23/06/2015
Registration date
07/08/2015
Last edited
02/11/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
COPD is a common chronic lung disease. Acute exacerbations (AECOPD) are often triggered by infection and are the second commonest reason for hospital admission in the UK. Severe exacerbations resulting in respiratory failure are associated with high mortality (death), which is reduced by 2-3 times by the use of non-invasive ventilation (NIV). Unfortunately the national COPD audit showed that of 26% of patients who met the criteria for ventilation, only 12% received it. In part, this reflects difficulty in accurately predicting outcome following NIV and widespread prognostic pessimism. Decisions about suitability for ventilation should be informed by reliable estimates of the patients’ chance of surviving the acute event and subsequent outcomes. Clinicians are unduly pessimistic as shown in a recent study (CAOS); actual six-month survival was four-fold better than predicted in some patients. Most survivors would choose ventilation again. Prognostic tools outperform clinicians’ estimates in most settings. The trialists will assess outcomes following AECOPD requiring ventilation and develop simple prognostic tools assessing in-hospital mortality.

Who can participate?
The study is retrospective (i.e. looking at events that have already occurred). It will include all those admitted consecutively to our trust with AECOPD requiring assisted ventilation from December 2008 onwards until at least 425 patients have been identified and included.

What does the study involve?
The patients included in the study are not exposed to any test or treatment only collection of data from case records. Any analysis or publication of data is anonymised . As such individual patient consent is not being sought for inclusion in the study. This approach has been approved by both patient focus group and a research ethics committee.

What are the possible benefits and risks of participating?
It is hoped that the successful development of a predictive tool will lead to better decision in a life-threatening situation. Nihilism will be challenged and more patients will consequently receive non-invasive ventilation. There are no perceived risks of participation.

Where is the study run from?
North Tyneside General Hospital (UK)

When is the study starting and how long is it expected to run for?
May 2014 to May 2016.

Who is funding the study?
Northumbria Healthcare NHS Foundation Trust (UK)

Who is the main contact?
Dr Tom Hartley
tomhartley@nhct.nhs.uk

Contact information

Dr Tom Hartley
Public

Research and Development
North Tyneside General Hospital
North Shields
NE29 8NH
United Kingdom

Phone +44 (0)444 811 8111
Email tom.hartley@nhct.nhs.uk
Dr Stephen Bourke
Scientific

North Tyneside General Hospital
North Shields
NE29 8NH
United Kingdom

Study information

Study designObservational single-centre study
Primary study designObservational
Secondary study design
Study setting(s)Hospital
Study typeOther
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleDerivation of a novel scoring system to predict inpatient mortality in exacerbations of chronic obstructive pulmonary disease requiring assisted ventilation.
Study objectivesClinicians' estimate of survival and prognosis is poor and is consistently outperformed by predictive tools. In acute exacerbations of COPD (AECOPD) requiring assisted ventilation the CAOS study highlighted pronostic nihilism. The national COPD audit showed that 26% of patients developed respiratory acidaemia but only 12% were ventilated. No predictive tool is routinely used in clinical practice in this group. The use of non-invasive ventilation is widespread and often initiated by the non specialist. Developing a predictive tool to augment decision making will reduce nihilism and increase use of a treatment shown to save lives, allow better prognostic information to be shared with a patient leading to shared decision making and in a small number of patients highlight the importance of palliative care.
Ethics approval(s)NRES Committee North West - Liverpool Central 29/5/2015, ref: 15/NW/0389
Health condition(s) or problem(s) studiedChronic obstructive pulmonary disease (COPD).
InterventionConsecutive patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) requiring assisted ventilation will be identified. Indices including; socio-demographic data, biochemical, clinical data and functional status will be collected. Variables related to mortality on univariate analysis will be identified. Eligible variables will be entered into backward stepwise logistic regression, with in-hospital mortality as the dependant variable. To ensure that the final model can be easily applied at the bedside, the final number of variables will be reduced to the minimum required to maintain prediction of in-hospital mortality. Performance will be assessed by AUROC curve. Mortality and readmission rates will be compared in patients with and without predefined characteristics, namely: Late failure of NIV, persistent hypercapnia, long term oxygen, long term ventilation.
Intervention typeMixed
Primary outcome measurePrediction of in-hospital mortality within the derivation cohort, assessed by the area under the receiver operating characteristic (AUROC) curve for tools developed using:
1. Indices available on admission
2. All indices up to and including the time of deterioration
Secondary outcome measures1. Comparison of the AUROC curves for both novel tools
2. Comparison of the AUROC curves for both novel tools to CAPS and APACHE II
3. 30 day, 90 day, 180 day and 1 year mortality
4. 30 and 90 day readmission rates
5. Comparison of outcomes in patients with, and without pre-defined characteristics:
5.1. Late failure of NIV (recurrent respiratory acidaemia, despite on-going ventilatory support)
5.2. Persistent hypercapnia
5.3. Long-term oxygen therapy
5.4. Long-term ventilation on discharge
Overall study start date01/05/2014
Completion date01/05/2016

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants425
Total final enrolment489
Key inclusion criteria1. Aged over 35 years
2. Smoking history greater than or equal to 10 pack years
3. Obstructive spirometry (FEV1/FVC < 0.7)
4. AECOPD primary diagnosis
5. Respiratory acidosis treated with NIV or IPPV (arterial blood gas pH <7.35, pCO2 > 6.0)
Key exclusion criteria1. Previous inclusion in the study
2. Other illness likely to limit survival to less than 1 year
Date of first enrolment01/07/2015
Date of final enrolment01/02/2016

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

North Tyneside General Hospital
Rake Lane
North Shields
NE29 8NH
United Kingdom
Wansbeck General Hopsital
Woodhorn Lane
Ashington
NE63 9JJ
United Kingdom

Sponsor information

Northumbria Healthcare NHS Foundation Trust
Hospital/treatment centre

c/o Caroline Potts
Research and Development
North Tyneside General Hospital
Rake Lane
North Shields
NE29 8NH
England
United Kingdom

ROR logo "ROR" https://ror.org/01gfeyd95

Funders

Funder type

Hospital/treatment centre

Research and Development Department, Northumbria Healthcare NHS Foundation Trust

No information available

Results and Publications

Intention to publish date01/08/2019
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planThis work is linked to a validation project. Publications will be prepared and presented upon completion of the validation study. Results of both studies will be presented together.
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 12/08/2021 02/11/2022 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

02/11/2022: Publication reference and total final enrolment added.
14/02/2020: No publications found, verifying study status with principal investigator.